Introduction

Stroke treatment is a race against time. When a blood clot blocks an artery in the brain, roughly two million neurons can die every minute that passes without intervention. Yet the standard procedure to remove that clot—a thrombectomy—is mostly available in large urban medical centers. Remedy Robotics, a San Francisco startup, is trying to change that equation by letting a surgeon guide a robotic catheter from a distance, potentially bringing emergency stroke care to smaller hospitals that lack specialist teams on site.

What Happened

Remedy Robotics has developed the N1 System, a robotic platform built to steer a flexible catheter through a patient’s blood vessels to the brain. Unlike traditional thrombectomy tools, which require a surgeon to physically manipulate a guide wire while watching a flat X-ray image, Remedy’s catheter is steerable on its own. Tiny wires pull the tip in different directions, and a computer-vision algorithm tracks its rotation. A CT scan can be overlaid on the live X-ray feed, giving the operator a three-dimensional view of the vessel path.

In a demonstration, the author operated the system using an Xbox-style controller while a plastic model of silicone tubing stood in for a human patient. Cofounders Jake Sganga and David Bell say the interface is intentionally intuitive, though they stress that ease of use is not the same as clinical success.

The company has already moved beyond models. In September 2025, Remedy conducted its first tests in human patients in Toronto. Ten people consented to nonemergency procedures. A neurosurgeon operated from a laptop, treating patients in an adjoining room, elsewhere in the same hospital, and at a separate facility across town. According to the company, the angiogram procedures were completed successfully and nearly twice as fast as the current standard.

Remedy recently announced $62 million in funding. The University of California system is expected to host upcoming clinical studies, beginning with on-site elective procedures such as treating unruptured aneurysms. Remote surgeries in Australia or within the University of California network could follow by the end of 2027.

Why This Matters

Only about one in ten patients who qualify for a thrombectomy actually receives one. In the United States, roughly one in five people lives more than an hour from a hospital that offers the procedure. In Alaska, the state’s only two thrombectomy centers are both in Anchorage, leaving more than half the population out of easy reach.

Remote robotics could help close that gap by allowing a specialist hundreds or thousands of kilometers away to guide the catheter in real time. Proponents argue this is especially suited to vascular procedures because, unlike open surgery, a lost connection does not cause immediate harm—the catheter can simply pause in place.

However, significant barriers remain. Rural areas often lack the high-speed, low-latency networks that remote surgery requires. Small hospitals may also lack neurologists, CT scanners, catheterization teams, and intensive-care units needed to support a thrombectomy program. Medium-sized regional hospitals with existing infrastructure may be more realistic early adopters.

Key Takeaways

  • Remedy Robotics’ N1 System uses a steerable robotic catheter and computer vision to navigate brain blood vessels without a traditional guide wire.
  • The company completed its first human patient tests in Toronto in September 2025, reporting successful procedures completed nearly twice as fast as usual.
  • Thrombectomy access is highly uneven: only about 10 percent of eligible patients receive the procedure, and many rural communities are over an hour from the nearest capable hospital.
  • Remote surgery depends on reliable, low-latency internet; Remedy targets a round-trip delay of no more than 150 milliseconds.
  • No robotics company has yet received full regulatory approval for telesurgery, and no remote operation has been performed on a patient in the United States.
  • Upcoming trials will start with on-site elective procedures before expanding to remote stroke interventions, potentially by late 2027.

Conclusion

Remedy Robotics is betting that the future of stroke care will not require every community to have a neurosurgeon on staff. By combining a steerable robotic catheter with remote operation, the company hopes to deliver thrombectomies to patients who would otherwise wait too long for treatment.

The path forward is still uncertain. Regulatory approval for telesurgery has not been granted to any company, network infrastructure in remote areas remains uneven, and questions persist about training, equity, and how to prioritize patients when a single distant surgeon could be needed in two places at once. Still, with new funding and clinical trials on the horizon, Remedy’s work offers a concrete glimpse of how robotics might one day extend emergency stroke care beyond the boundaries of geography.